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Abstract
Airway inflammation increases during acute exacerbations of COPD. Extrinsic factors, such as
airway infections, increased air pollution, and intrinsic factors, such as increased oxidative stress
and altered immunity may contribute to this increase. The evidence for this and the potential
mechanisms by which various aetiological agents increase inflammation during COPD
exacerbations is reviewed. The pathophysiologic consequences of increased airway inflammation
during COPD exacerbations are also discussed. This review aims to establish a cause and effect
relationship between etiological factors of increased airway inflammation and COPD exacerbations
based on recently published data. Although it can be speculated that reducing inflammation may
prevent and/or treat COPD exacerbations, the existing anti-inflammatory treatments are modestly
effective.
Background
Exacerbations are a cardinal feature of the natural history
of moderate and severe Chronic Obstructive Pulmonary
Disease (COPD)[1]. Patients with frequent exacerbations
have significantly lower quality of life and increased mor-
bidity and mortality rates [1-4]. Although the effect of
COPD exacerbations on lung function has been ques-
tioned in the past, recent evidence suggests that exacerba-
tions accelerate long-term decline in lung function,
specifically in smokers [5-7]. The mechanism of this accel-
eration remains largely unknown.
Treatment decisions for COPD patients are frequently
made according to exacerbation rates. In the ATS/ERS
guidelines it is stated that patients with frequent exacerba-
tions should be initiated a trial of inhaled steroids[8]. Sys-
temic steroids should be administered during acute
COPD exacerbations, both in the inpatient and outpatient
setting. These treatment strategies indicate the central role
of inflammation in the pathogenesis of exacerbations.
Although evidence for increased inflammation on COPD
exacerbations has been reviewed previously, there has
been little focus on why inflammation increases and
which the consequences of this increase are[9,10]. Inves-
tigating further these important questions may help estab-
lish a cause and effect relationship between inflammation
and COPD exacerbations. The primary aim of this review
is to summarize emerging explanations for why inflamma-
tion is increased during COPD exacerbations. For practi-
cal purposes an attempt is made to categorize aetiological
factors of increased inflammation into extrinsic or intrin-
sic, as it can be seen in table 1. A secondary aim is to try to
explain how increased inflammation is associated with the
pathophysiology of COPD exacerbations.
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Aetiology of increased inflammation on 
exacerbations
Extrinsic factors
1. Airway infections
1a Bacterial infections
Bacterial infections are generally considered to be the
most common causes of COPD exacerbations. It is esti-
mated that more than 40% of all exacerbations are of bac-
terial origin[9,11,12]. Accordingly, antibiotics should be
administered in inpatients and outpatients with acute
COPD exacerbation and changes in sputum characteris-
tics suggestive of bacterial infection[8].
The most common bacteria connected to COPD exacerba-
tions are non-typable H. Influenzae, S. Pneumoniae, and
M. Cattarhalis[9,11,12]. The same bacteria often colonize
the nasal mucosa and pharynx of healthy individuals, but
in smokers and in patients with COPD impaired mucocil-
liary clearance and innate immunity allow these patho-
gens to colonize the lower airways[13]. COPD
exacerbations may be triggered by the acquisition of a new
bacterial species or by an increase in the absolute number
of the same bacteria that colonize the airways or by the
acquisition of a different strain from the same bacterial
species [14-16].
Airway bacteria initiate airway inflammation through sev-
eral interconnecting mechanisms. The surface of bacteria
allows the complement system to be activated through the
alternative pathway, while specific surface molecules of
the bacteria, called Pathogen-Associated Molecular Pat-
terns (PAMPs), bind to pattern recognition receptors on a
variety of leukocytes and initiate signalling pathways that
lead to the activation of NF-κB and production of proin-
flammatory cytokines[17]. Once activated, innate immu-
nity can trigger both cell-mediated and antibody-
mediated adaptive immune responses. This cascade of
events leads to increased blood flow to tissue, increased
temperature, redness and swelling which characterize
inflammation.
A significant number of studies in stable COPD patients
suggest that airway bacterial infections are associated with
increased airway inflammation(18–21). Finding a rela-
tionship between bacteria and inflammation on stable
COPD adds weight to the argument that bacteria may play
a causative role in airway inflammation during COPD
exacerbations.
Soler et al used protected specimen brush and bronchoal-
veolar lavage sampling to determine inflammatory cell
counts, levels of cytokines concentrations and microbial
patterns in stable COPD patients and found that increased
neutrophils and tumour necrosis factor-alpha (TNF-
alpha) levels may be related to bronchial coloniza-
tion[18]. Increased TNF-alpha, as well as myeloperoxi-
dase (MPO) and interleukin-8 (IL-8) levels have been
specifically related with H. Influenzae infection, as shown
by Bresser et al[19]. However, in that study all mediators
were measured in frozen sputum and MPO and IL-8 levels
were only retrospectively compared to non-infected
patients. In fresh sputum samples from COPD patients R.
Stockley and his group demonstrated that MPO, neu-
trophil elastase (NE) activity, IL-8 and LTB4 levels are pos-
itively related to sputum bacterial load[20]. Moreover, the
type of organism affected sputum MPO levels and NE
activity; MPO levels were relatively increased in the pres-
ence of Ps. Aeruginosa compared to H. Influenzae and to
M. Catarrhalis. There have been also reports for decreased
secretory leukocyte protease inhibitor (SLPI) in sputum
samples from COPD patients colonised with bacte-
ria[20,21]. Upper airways inflammation in COPD is also
increased when there is bacterial colonization[22]. All
these results taken together suggest that bacteria are
Table 1: Aetiology of increased airway inflammation during COPD exacerbations
EXTRINSIC FACTORS INTRINSIC FACTORS
1. Acute airway infections
a. Bacterial
H. Influenzae
S. pneumoniae
M. Cattarhalis
b. Viral
Rhinoviruses
Picornaviruses
RSV
Influenza A, B
Coronaviruses
c. Atypical
C. Pneumonia
2. Air pollution
1. Oxidative stress
2. Altered immunity
Tc1/Tc2 imbalance
3. Increased inflammation on stable state
Bronchiectasis
Bacterial ColonizationRespiratory Research 2006, 7:80 http://respiratory-research.com/content/7/1/80
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actively involved in the mechanisms of increased inflam-
mation in stable COPD. It would be logical to assume a
similar association for COPD exacerbations.
A large prospective longitudinal study by Sethi et al
addressed the hypothesis that patients with bacterial-pos-
itive exacerbations show increased inflammation com-
pared to bacterial-negative exacerbations[23]. Among H.
Influenzae, H. Parainfluenzae and M. Catarrhalis positive
exacerbations, H. Influenzae and M. Catarrhalis demon-
strated higher sputum TNF-alpha and NE levels compared
to bacterial-negative exacerbations. Moreover, increased
NE levels above a certain level could distinguish bacterial
from non-bacterial exacerbations with 71% sensitivity
and 84% specificity. Others have failed to report any dif-
ference in sputum NE levels and other fluid-phase media-
tors between patients with H. Influenzae exacerbations or
bacterial-negative exacerbations[24]. This discrepancy
may be due to differences in sputum induction time or in
sputum processing or in the assays used for the detection
of fluid-phase mediators. Another intriguing hypothesis is
that different strains of the same pathogens may induce
different levels of inflammation and subjects taking part
in different studies might have been infected by different
strains of H. Influenzae. It was recently shown that H.
Influenzae strains isolated from COPD patients during
exacerbation induce more inflammation than strains of
the same pathogen isolated from colonizers[16]. The
close association between airway infections and increased
inflammation during COPD exacerbations has been fur-
ther confirmed by a report of increased systemic inflam-
mation in infected patients during exacerbation[25].
Consistent with these observations, airway inflammation
can be decreased with treatment of the infection. Early evi-
dence came from a relatively small study, which showed
that neutrophilic mediators' levels may decrease after
treatment of bacterial exacerbations[26]. Gompertz et al
confirmed that there are significant decreases in neu-
trophilic inflammatory mediators after treatment of puru-
lent exacerbations[27]. Most importantly, White et al
studied patients with bacterial exacerbations and demon-
strated a significant fall in sputum leukotriene B4 (LTB4)
levels and an increase in SLPI levels in patients in whom
bacteria were eradicated, but not in those in whom bacte-
ria persisted on stable state[24]. Moreover, MPO and
LTB4 levels were significantly lower and SLPI levels signif-
icantly higher in patients with treated compared to
patients with untreated bacterial infections on stable state.
In conclusion, three major findings support the hypothe-
sis that bacterial infections are actively implicated in the
mechanisms of increased airway inflammation during
COPD exacerbations: 1) bacterial infections increase air-
way inflammation in colonized stable COPD patients 2)
bacterial-positive exacerbations show increased inflam-
mation (particularly of neutrophilic type) compared to
bacterial-negative exacerbations and 3) eradication of
bacteria after a bacterial exacerbation is accompanied by a
significant decrease in airway inflammation. A summary
of these findings is presented in table 2.
1b Viral infections
Respiratory viruses are important triggers of COPD exac-
erbations. Initial studies using serology and cell cultures
for detecting viral infections suggested that 30% of COPD
exacerbations are related to viral infections [28-30]. Later
studies using the more sensitive method of reverse tran-
scriptase polymerase chain reaction showed that 40%–
50% of COPD exacerbations may be secondary to viral
infection[31,32]. Rhinoviruses, picornaviruses, respira-
tory syncytial virus, influenza A and B and coronaviruses
are more frequently detected[31,32].
Possible mechanisms of viral-induced inflammation have
been described. The airway epithelial cell is the principal
host cell for most respiratory viruses[33]. Viral replication
in the epithelial cell triggers intracellular signalling path-
ways, including activation of NFκB, which leads to
increases in the secretion of multiple cytokines and
recruitment of multiple leukocytes to the airways[33].
Antigen presenting cells are of particular importance,
because binding of viruses to these cells induces innate
and adaptive immune responses and T lymphocyte activa-
tion[34].
There is convincing data that viruses induce inflammation
in asthma[35]. In animal models of emphysema, latent
adenoviral infection amplifies the emphysematous
destruction and increases the inflammatory response[36].
In stable COPD latent adenoviral infection has been asso-
ciated with severe emphysema and increased inflamma-
tion[37]. The group of J Wedzicha showed that viral
infections might be implicated in the mechanisms of
increased airway and possibly systemic inflammation dur-
ing COPD exacerbations. Plasma IL-6 and fibrinogen lev-
els were higher during viral than non-viral exacerbations,
although the difference just failed to reach statistical sig-
nificance[31]. However, in that study viruses were
detected in nasal samples and it has been shown that in
COPD patients respiratory viruses are detected more fre-
quently in induced sputum than in nasal lavage[32,38].
When rhinovirus infection was detected in induced spu-
tum samples a significant correlation was demonstrated
between rhinovirus infection and increased sputum IL-6
levels on COPD exacerbations[38].
Further to these observations, two recent studies showed
that viral airway infections during COPD exacerbations
are related to airway eosinophilia[39,40]. This new find-Respiratory Research 2006, 7:80 http://respiratory-research.com/content/7/1/80
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ing may be of particular clinical importance as airway
eosinophilia could be used as an indicator of viral infec-
tion during an exacerbation. The important role of eosi-
nophils in the pathogenesis of COPD exacerbations is
further supported by studies in bronchial biopsies and
sputum samples, which show increased eosinophil num-
bers and eosinophil mediators in COPD patients during
exacerbations [41-46]. Eosinophils may be actively
involved in the pathogenesis of viral-induced COPD exac-
erbations through the release of destructive enzymes, reac-
tive oxygen species and inflammatory mediators.
1c Atypical bacteria
Atypical pathogens with potential importance in acute
exacerbations include M. Pneumoniae, C. Pneumoniae
and Legionella spp. Considerable confusion exists in the
literature regarding the significance of these potential
pathogens in acute exacerbations of COPD[47]. This is
partly due to differences in the techniques used to detect
the presence of atypical infections. When a fourfold
increase in antibody titter or a positive culture or RT-PCR
is used, M. Pneumoniae and Legionella are rare and C.
Pneumoniae infection may be involved in up to 9% of
COPD exacerbations[30,48-50]. Moreover, chronic colo-
nization with C. Pneumoniae may be associated with a
higher rate of COPD exacerbations[51]. C. Pneumonia
infection can amplify inflammation in the airways of
COPD patients by stimulating the production and expres-
sion of cytokines, chemokines and adhesion mole-
cules[52]. However, clear evidence showing a direct
relationship between increased inflammation and C.
Pneumoniae infection during COPD exacerbations is yet
lacking[50].
2. Increased air pollution
Epidemiologists have linked ambient particulate air pol-
lution (PM) exposure with exacerbations of pre-existing
pulmonary diseases, such as COPD[53]. PM-mediated
enhancement of airway inflammation is a central patho-
genetic mechanism by which PM exposure leads to exac-
erbation of inflammatory pulmonary diseases [54-56]. It
has been suggested that PM exposure induces lung inflam-
mation by an increase in Reactive Oxygen Species[57,58].
To the best of our knowledge there are no in vivo studies
on the effect of PM exposure on airway inflammation in
COPD patients. There is also lack of information on air-
way inflammation during PM exposure induced COPD
exacerbations, which may be due to difficulties in defin-
ing such exacerbations.
Intrinsic factors
1. Increased oxidative stress
An imbalance between oxidants and antioxidants may be
involved in the development of COPD exacerbations.
Almost a decade ago Rahman et al showed that plasma
Trolox equivalent antioxidant capacity is decreased in
patients presenting with acute exacerbation of COPD[59].
Recent reports suggest that 8-isoprostane levels are
increased in exhaled breath condensate of COPD patients
during exacerbations, while levels of the antioxidant
enzyme glutathione(GSH) in bronchoalveolar lavage
fluid are decreased[60,61]. Oxidative stress may be closely
associated to increased inflammation during exacerba-
tions[60,62].
Oxidant stimuli induce cellular expression of inducible
nitric oxide synthase and heme-oxygenase-1(HO-1) and
increase nitrotyrosine formation. We have shown that
there is increased HO-1 expression and nitrotyrosine for-
mation in the airways of COPD patients during severe
exacerbations relatively to stable state and that this is
accompanied by an increase in indices of neutrophilic
inflammation, i.e. neutrophil numbers, MPO and IL-8
levels[62]. Evidence for a close association between oxida-
tive stress, airway neutrophilia and increased IL-8 during
severe COPD exacerbations is also supported by Drost et
al[60]. A certain limitation in the study by Drost et al is
the fact that different patients were examined on exacerba-
tion and on stable state.
Oxidative stress induces the transcription of various
inflammatory factors, such as nuclear factor-kappaB (NF-
κB) and activator protein-1 (AP-1)[63]. It has been shown
that NF-κB DNA binding in sputum inflammatory cells is
Table 2: Studies showing an association between bacterial infections and airway inflammation in stable COPD and on exacerbations
Year Author Main finding
1999 Soler Increased NEU, TNF-a in colonized pts
2000 Bresser Increased TNF-a, MPO, IL-8 in H. Influenzae colonized pts
2000 Hill Positive relation between MPO, NE, IL8, LTB4 and bacterial load in stable state. Increased MPO and decreased SLPI in Ps. 
Aeroginosa colonized pts
2000 Sethi Increased TNFa, NE in H. Influenae and M. Catarrhalis exacerbations
2000 Crooks Decrease in MPO, IL8, LTB4, after treatment of bacterial exacerbations
2001 Gombertz Decrease in LTB4 after treatment of purulent exacerbations
2002 Patel Positive relation between IL8 and bacterial load. Decreased SLPI in colonized pts
2003 White Decrease in LTB4, increase in SLPI after bacteria eradication on exacerbationsRespiratory Research 2006, 7:80 http://respiratory-research.com/content/7/1/80
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increased during COPD exacerbations[64]. Other investi-
gators have reported increased nuclear localisation of p65,
which is a signal of NF-κB activation, in sputum macro-
phages during COPD exacerbations[65]. NF-κB is impor-
tant for transcription of IL-8 gene and oxidative stress may
induce or amplify airway neutrophilia by inducing the
transcription of IL-8 gene[66]. In support of this hypoth-
esis both we and Drost et al have found increased IL-8 lev-
els and neutrophil numbers associated with increased
oxidative stress on severe COPD exacerbations[60,62].
Activated neutrophils and other inflammatory cells can in
turn release reactive oxygen species and increase airway
oxidative stress. Because oxidative stress can induce
inflammation and vice versa, it is not clear which of the
two, oxidative stress or inflammation, is primarily
involved in the mechanisms of COPD exacerbations-[the
chicken and egg problem].
2. Altered immunity
Alterations in innate and adaptive immunity are impli-
cated in COPD pathogenesis[67]. Evidence favouring par-
ticipation of the adaptive immune response in COPD
includes the several reports of increased numbers of T-
lymphocytes, specifically CD8+ve T-cells with a "type
1"profile [68-71]. It is still unknown whether these alter-
ations are triggered by cigarette smoking, viral infections,
or there is a genetic predisposal. We have recently shown
that CD8+ve T lymphocytes may mediate their destructive
effects in COPD through increased perforin expression
and cytotoxic activity[72]. It would be reasonable to
assume that lymphocytes may be implicated in the mech-
anisms of increased inflammation during COPD exacer-
bations.
According to our observations changes in lymphocyte
subpopulations occur during severe COPD exacerba-
tions[73]. In specific, there is a further increase in CD8+ve
T cells and this is rather associated with increased CD8+ve
type 2 cells compared to type 1. This finding suggests that
Tc1 and Tc2 responses may fluctuate in relation to the dif-
ferent phase (exacerbation versus stable state) of the dis-
ease in the same patient. Similar observations have been
made in other inflammatory diseases[74]. A relative
increase of Tc2 versus Tc1 cells may result in impaired
immunity, increased susceptibility to viral infections and
increased inflammation [75-77].
Although Saetta et al also found increased T cell numbers
in endobronchial biopsies from chronic bronchitis
patients on mild exacerbations, no difference was
detected in CD4 or CD8+ve cell numbers[45]. This dis-
crepancy may be attributed to the fact that we examined
sputum samples (not biopsies) from COPD patients (not
chronic bronchitis) on severe exacerbation (not mild
exacerbation). Moreover, Saetta et al compared different
patients on exacerbation and on stable state, which could
be a limitation in their study. However, finding increased
T cell numbers still adds evidence to the argument that
immune responses may be involved in the mechanisms of
increased airway inflammation during COPD exacerba-
tions.
3. Increased baseline levels of inflammation
It would be logical to assume that small increases in air-
way inflammation in patients with already increased base-
line levels of inflammation can easily trigger a COPD
exacerbation. This presumes the existence of an inflam-
matory threshold, above which exacerbation occurs. In
relation to this hypothesis, Bhowmik et al showed that
COPD patients with frequent exacerbations (≥ 3 episodes/
year) have increased baseline sputum IL-6 and IL-8 lev-
els[78]. However, it was not examined whether this was
related to bacterial colonization, as bacterial colonization
can increase airway inflammation and exacerbation rates.
The same group also showed faster rises over time in
plasma fibrinogen and sputum IL-6 in patients with fre-
quent exacerbations[79].
On the contrary, Gombertz et al did not detect any differ-
ence in neutrophilic mediators (including IL-8) between
frequent (≥ 3 episodes/year) and infrequent exacerba-
tors[80]. Interestingly, when patients with bronchiectasis
were excluded from the analysis, SLPI was found to be
lower in COPD patients with frequent exacerbations,
which suggests that COPD patients with bronchiectasis
may represent a distinct group. Fujimoto et al also report
no difference in baseline IL-8 and markers of eosinophilic
inflammation between stable and unstable COPD
patients[42]. However, results between this and other
studies are not comparable due to lower exacerbation
rates (mean 1 episode/year) in the unstable COPD group
in this study.
In conclusion, data relating baseline airway inflammation
to exacerbation frequency are rather controversial. Part of
the existing confusion may be due to significant heteroge-
neity among COPD patients and to the existence of sev-
eral factors, like bacterial colonization and bronchiectasis
that may increase airway inflammation. In particular,
COPD patients with bronchiectasis may represent a dis-
tinct group characterized by higher rates of bacterial colo-
nization, increased baseline levels of airway
inflammation and longer symptom recovery times at
exacerbation[81].
Inflammation and pathophysiology of exacerbations
Episodes of COPD exacerbations are characterized by an
acute increase in a patient's baseline dyspnoea, cough
and/or sputum production[8]. Severe exacerbations areRespiratory Research 2006, 7:80 http://respiratory-research.com/content/7/1/80
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also associated with worsening of pulmonary gas
exchange that may lead to hypoxemia with or without
hypercapnia[82]. In order to support a role for airway
inflammation in COPD exacerbations the mechanisms
which are induced by airway inflammation need to be
related to the symptoms and pathophysiology of exacer-
bations.
Increased airway inflammation induces many pathologic
changes on the airways. Accumulation of inflammatory
cells in the airway mucosa by itself causes airway wall
thickening. Inflammatory cells can release potentially
harmful mediators, such as proteases and reactive oxygen
species[83]. Neutrophil and eosinophil products, like
MPO, NE and eosinophilic cationic protein (ECP), have
been found increased on exacerbations, and can cause
inflammatory damage and increased permeability of the
bronchial mucosa, resulting in airway oedema and pro-
tein exudation[20,42,62,84]. Inflammatory mediators,
like ECP, can also induce bronchoconstriction by increas-
ing achetinocholine release from parasynmpathetic
nerves, while others, like NE, increase mucus secre-
tion[85,86]. Furthermore, mediators of inflammation
enhance coughing[87]. Potentially harmful mediators
may be released not only by inflammatory cells but also
by resident cells. For example, endothelin (ET)-1, which
has been found increased on exacerbations, can be
released by epithelial cells and stimulates mucus secretion
and bronchial hyperesponsiveness[50]. The cascade of the
above events leads to significant airway narrowing and
increased airway secretions, while the patient suffers from
increased cough, sputum, and/or increased dyspnea. The
mechanisms of dyspnea are not entirely understood yet,
but may be also associated with excessive airway narrow-
ing and dynamic hyperinflation due to increased inflam-
mation [88-90].
A brief summary of the pathophysiologic events that may
link airway inflammation to the symptoms of COPD
exacerbations and to respiratory failure is given in figure
1. Airway narrowing, caused by increased inflammation,
leads to expiratory flow limitation and dynamic hyperin-
flation. Dynamic hyperinflation in turn increases work of
respiratory muscles and oxygen consumption, resulting in
decreased mixed venous oxygen tension[91]. Airway nar-
rowing also increases ventilation/perfusion inequality,
because a greater proportion of blood flow is diverted
through lung units with low V'/Q' ratios[91]. The combi-
Schematic presentation of the main pathophysiologic events of COPD exacerbations, starting from increased airway inflamma- tion Figure 1
Schematic presentation of the main pathophysiologic events of COPD exacerbations, starting from increased airway inflamma-
tion.Respiratory Research 2006, 7:80 http://respiratory-research.com/content/7/1/80
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nation of increased ventilation/perfusion inequality and
decreased mixed venous oxygen tension significantly
worsen gas exchange in patients with severe COPD exac-
erbations.
Increased airway inflammation would be also expected to
increase lung tissue oxygen demand and oxygen con-
sumption. In patients with acute lung injury no relation
has been found between pulmonary oxygen consumption
and lung inflammation, but there is no relevant data in
COPD exacerbations[92].
Anti-inflammatory therapy for exacerbations
Despite the increasing recognition of the importance of
airway inflammation in the development of COPD exac-
erbations, there is still confusion regarding the role of
anti-inflammatory strategies in the prevention and treat-
ment of COPD exacerbations[93,94]. There are studies
showing a beneficial effect of inhaled steroids in prevent-
ing COPD exacerbations and systemic steroids in treating
acute exacerbations, however the overall benefits for
COPD patients in these studies are generally modest [95-
97]. Considering that inflammation in stable COPD is
steroid resistant, this should not come as a great sur-
prise[98]. Although the majority of COPD patients
respond modestly to steroid therapy, there might be sub-
group of patients, those with eosinophilic pattern of
inflammation during exacerbations that may benefit the
most from steroid administration. There is already evi-
dence that stable patients with high sputum eosinophil
counts are steroid responsive, but there is no relevant data
on COPD exacerbations[99,100]. Identifying patients that
may benefit from systemic steroid administration during
exacerbations is of great importance, due to the serious
adverse events frequently observed with this kind of treat-
ment[97].
Other drugs with anti-inflammatory properties, like meth-
ylxanthines and mucolytic agents seem not to be effective
on COPD exacerbations[8]. B-agonists are mainly admin-
istered as bronchodilators, although they may also have
an anti-inflammatory role[101]. Novel drugs aimed at
inhibiting targets, including NO synthase, phosphodieste-
rase 4, proteases and various inflammatory mediators
have not been tested during exacerbations yet.
Conclusion
It has been long postulated that airway inflammation may
be increased during COPD exacerbations and this may be
involved in the pathophysiology of exacerbations. There
is now sufficient data to support such a hypothesis. Firstly,
there are accumulating observations for increased inflam-
mation during COPD exacerbations. Secondly, specific
aetiological factors for this increase have been identified.
Thirdly, possible mechanisms that may link airway
inflammation with the pathophysiology of exacerbations
have been unmasked. Despite significant advances in our
understanding of the role of inflammation in COPD exac-
erbations, the existing anti-inflammatory treatments
remain modest and there is little overall benefit for the
patient. Further research is needed to target therapies to
the appropriate patient populations and to develop new
therapeutic strategies.
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